Medpace's Q1 2025 Earnings Call: Navigating Contradictions in Business Environment, Cancellation Rates, and Book-to-Bill Expectations
Wednesday, Apr 23, 2025 9:44 pm ET
2min read Business environment and cancellation rates, book-to-bill ratio expectations, competitive environment and pricing, issues with funding uncertainties are the key contradictions discussed in Medpace's latest 2025Q1 earnings call.
Revenue and Backlog Trends:
- medpace reported revenue of $558.6 million for Q1 2025, representing a 9.3% year-over-year increase.
- The ending backlog as of March 31, 2025, was approximately $2.8 billion, a 2.1% decrease from the prior year.
- The decrease in backlog was due to high pipeline cancellations in prior quarters, impacting Q1 and future projected backlog net awards.
Book-to-Bill Ratio and Cancellations:
- The company's net book-to-bill ratio was 0.90 in Q1 2025, indicating a decrease in net new business awards entering backlog.
- Cancellations were modestly elevated in Q1, with pre-backlog cancellations being significantly worse, affecting the book-to-bill ratio and backlog growth.
Financial Performance and Margin Trends:
- EBITDA for Q1 2025 increased by 2.6% year-over-year to $118.6 million, but the EBITDA margin decreased to 21.2%, down from 22.6% in the prior year period.
- The margin decrease was attributed to employee-related costs and foreign exchange impacts due to a weakening U.S. dollar.
Share Repurchase and Capital Allocation:
- Medpace repurchased approximately 1.19 million shares or $389.8 million during the first quarter, with $344.8 million remaining under the share repurchase authorization program.
- The company continues to take an opportunistic approach to share repurchases, leveraging share price volatility for strategic capital allocation.
MEDP Total Revenue YoY, Total Revenue
Revenue and Backlog Trends:
- medpace reported revenue of $558.6 million for Q1 2025, representing a 9.3% year-over-year increase.
- The ending backlog as of March 31, 2025, was approximately $2.8 billion, a 2.1% decrease from the prior year.
- The decrease in backlog was due to high pipeline cancellations in prior quarters, impacting Q1 and future projected backlog net awards.
Book-to-Bill Ratio and Cancellations:
- The company's net book-to-bill ratio was 0.90 in Q1 2025, indicating a decrease in net new business awards entering backlog.
- Cancellations were modestly elevated in Q1, with pre-backlog cancellations being significantly worse, affecting the book-to-bill ratio and backlog growth.
Financial Performance and Margin Trends:
- EBITDA for Q1 2025 increased by 2.6% year-over-year to $118.6 million, but the EBITDA margin decreased to 21.2%, down from 22.6% in the prior year period.
- The margin decrease was attributed to employee-related costs and foreign exchange impacts due to a weakening U.S. dollar.
Share Repurchase and Capital Allocation:
- Medpace repurchased approximately 1.19 million shares or $389.8 million during the first quarter, with $344.8 million remaining under the share repurchase authorization program.
- The company continues to take an opportunistic approach to share repurchases, leveraging share price volatility for strategic capital allocation.
Ask Aime: "Medpace's earnings reveal high cancellations and decreased backlog, impacting future revenue."
